<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Resistance of &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt; to the macrolides, azalides, and lincosamides
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Resistance of
       <i>
        Streptococcus pneumoniae
       </i>
       to the macrolides, azalides, and lincosamides
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Resistance of
        <i>
         Streptococcus pneumoniae
        </i>
        to the macrolides, azalides, and lincosamides
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel M Musher, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas M File, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Streptococcus pneumoniae
         </em>
         (pneumococcus), the most common cause of bacterial respiratory tract infections in children and adults, was susceptible to virtually all antibiotics used in treating such infections until outbreaks of infection due to antibiotic-resistant pneumococci were recognized in South Africa in the late 1970s [
         <a href="#rid1">
          1,2
         </a>
         ]. Although the responsible organisms were called penicillin-resistant pneumococci (PRP), they had acquired genetic material that encoded resistance both to penicillin and to other commonly used antibiotics.
        </p>
        <p>
         In the ensuing decades, resistance of pneumococci to several clinically relevant classes of antibiotics has evolved from an ominous medical curiosity to a worldwide health problem.
        </p>
        <p>
         Macrolides, azalides, and lincosamides are related drugs that inhibit protein synthesis at the same site in the bacterial ribosome and are generally active against the same microorganisms. Macrolides and azalides are (or, at least, used to be) generally active against
         <em>
          S. pneumoniae
         </em>
         ,
         <em>
          Haemophilus influenzae
         </em>
         ,
         <em>
          Moraxella catarrhalis
         </em>
         ,
         <em>
          Legionella
         </em>
         species,
         <em>
          Chlamydia pneumoniae
         </em>
         , and
         <em>
          Mycoplasma pneumoniae
         </em>
         .
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         , the only lincosamide currently in use, is effective against most pneumococci but is not active against such pathogens as
         <em>
          H. influenzae
         </em>
         and
         <em>
          M. catarrhalis
         </em>
         .
        </p>
        <p>
         The mechanisms of action and resistance of pneumococci to macrolides, azalides, and lincosamides, as well as clinical data on the outcome of therapy with these drugs for otitis, sinusitis, acute exacerbations of chronic bronchitis, pneumonia, and meningitis, will be reviewed here. Resistance to the other classes of drugs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to beta-lactam antibiotics"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7028.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MACROLIDES AND AZALIDES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first of the macrolides,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , is poorly tolerated. After oral administration, erythromycin causes gastrointestinal distress and is not reliably absorbed; it also frequently causes thrombophlebitis after intravenous administration. As a result, erythromycin has been largely replaced by
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , a newer macrolide, and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , an azalide. It is important to note that most pneumococci that are resistant to erythromycin are also resistant to the newer macrolides and the azalides.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Mechanisms of action and resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macrolides and azalides insert into a pocket of the 23S subunit of the 50S ribosome specifically by attaching at domain V of the peptidyl transferase loop, thereby blocking protein assembly. In doing so, these drugs exert a bactericidal effect on
         <em>
          S. pneumoniae
         </em>
         [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Acquisition of genetic material, designated
         <em>
          ermB
         </em>
         or
         <em>
          mefA
         </em>
         , encodes for resistance to macrolides and azalides [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          ermB
         </em>
         encodes methylation of a base in domain V of the 23S ribosomal ribonucleic acid (rRNA) (A2058) that alters the site of attachment such that the macrolide no longer recognizes and binds to the ribosome. This lack of binding creates high-level resistance (&gt;64 mcg/mL); thus, increasing the dose with a resulting increase in the concentration of the drug has little effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          mefA
         </em>
         encodes a pump by which the organism expels macrolides. This resistance is at a lower level (usually &lt;16 mcg/mL); high antibiotic concentrations might be expected to overcome the pump, forcing enough antibiotic into the bacterium to exert an antibacterial effect.
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         are more active against pneumococci than is
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , and it has been thought that they might be effective in vivo against
         <em>
          mefA
         </em>
         -containing strains. However, the level of resistance in these strains has been rising [
         <a href="#rid5">
          5
         </a>
         ], and it seems increasingly likely that the resistance observed in vitro will be clinically meaningful.
        </p>
        <p>
        </p>
        <p>
         Some resistant isolates carry both
         <em>
          ermB
         </em>
         and
         <em>
          mefA
         </em>
         . In a small percentage of isolates, other mutations induce resistance, for example, by causing other base substitutions in domain V or by altering protein sequences within or adjacent to the macrolide binding site, especially involving ribosomal proteins L4 and L22 [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Prevalence of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 1998, only 18 percent of pneumococcal isolates were resistant to macrolides [
         <a href="#rid8">
          8
         </a>
         ]. Between 1998 and 2011, there was a steady increase in the rate of resistance such that, in 2011, 25 to 45 percent of pneumococci in the United States were resistant to macrolides. By 2019, resistance rates were on average about 40 percent in the United States [
         <a href="#rid9">
          9-12
         </a>
         ].
        </p>
        <p>
         For reasons that may be related to cultural differences within the health care professions relating to antibiotic use, there is substantial
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fresistancemap.cddep.org%2FCountryPageSub.php%3FcountryId%3D38%26country%3DUnited%2BStates&amp;token=ChoKhAb3KcQzKnVjFV17tBQhD07U9lnNcaeVCs0Uzkv7h5GjLiOH6Tk7htAHrcE9tXtvoau8w3lwekbGlu9chbet%2B1JKB%2BZkJDeEb%2F2Fj%2FwaHwDB3IZjxQNcRVajR9DZ&amp;TOPIC_ID=7033" target="_blank">
          regional variation
         </a>
         [
         <a href="#rid13">
          13,14
         </a>
         ]. Resistance is attributable to
         <em>
          mefA
         </em>
         and
         <em>
          ermB
         </em>
         in approximately equal numbers of isolates, with about 25 percent of them carrying both elements [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Although the introduction of the pneumococcal conjugate vaccine into the vaccine schedule for children in the United States in 2000 was anticipated to reduce resistance by leading to the elimination of resistant nasal carriage strains, this appears not to have been the case, since "replacement" strains that have emerged also have a high rate of resistance [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         A higher proportion of pneumococci in Europe are macrolide resistant and, in the majority of phenotypically resistant isolates,
         <em>
          ermB
         </em>
         is responsible [
         <a href="#rid16">
          16
         </a>
         ]. Rates of resistance are lower in Canada than in the United States and higher in the Far East than in Europe [
         <a href="#rid17">
          17-19
         </a>
         ]. The rates of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         resistance in Asia were 55 percent overall, 92 percent in Vietnam, and 70 percent in Japan [
         <a href="#rid18">
          18,19
         </a>
         ]. In the study from Japan, half of the isolates were highly resistant (minimum inhibitory concentration [MIC] ≥16 mcg/mL), and resistance was most frequently identified among children younger than two years of age [
         <a href="#rid19">
          19
         </a>
         ]. Similarly, high rates of resistance are now reported in Eastern Europe as well [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         A prospective cohort study of several thousand patients with invasive pneumococcal infection identified apparent risk factors for the acquisition of macrolide-resistant pneumococcal strains [
         <a href="#rid21">
          21
         </a>
         ]. These include previous use of
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (odds ratio [OR] 9.9),
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         (OR 3.9), penicillin (OR 1.8), and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (OR 2.1).
        </p>
        <p>
         In another study, following mass
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         administration (a single dose of 20 mg/kg every three months for one year) for trachoma in children in Ethiopia, the diversity of pneumococcal sequence types detected by multilocus sequence typing of nasopharyngeal swab specimens decreased significantly, and resistant clones present before mass azithromycin administration increased in frequency (from 5 percent before treatment to 15 percent after treatment) [
         <a href="#rid22">
          22
         </a>
         ]. Higher rates of pneumococcal resistance to macrolides were also found following mass administration of azithromycin in Niger [
         <a href="#rid23">
          23,24
         </a>
         ]. These studies support the hypothesis that antibiotic selection pressure results in clonal expansion of existing resistant strains among pneumococci colonizing the nasopharynx.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Resistance and the outcome of therapy
         </span>
        </p>
        <p class="headingAnchor" id="H2415739366">
         <span class="h3">
          Otitis media
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful studies of otitis media have established a close relationship between the susceptibility of the infecting pneumococcus and the response to macrolides [
         <a href="#rid25">
          25-28
         </a>
         ]. One review summarized an extensive clinical experience by stating that
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         cured nearly 95 percent of cases of otitis media when the organisms were susceptible to the drug but only 20 percent when they were not [
         <a href="#rid27">
          27
         </a>
         ]. In one study, for example, azithromycin (10 mg/kg on the first day and 5 mg/kg for four additional days) cured 23 of 25 children who had pneumococcal otitis media due to a fully susceptible organism (MIC &lt;0.5 mcg/mL) compared with three of eight children whose infecting organism was only susceptible to &gt;2 mcg/mL [
         <a href="#rid25">
          25
         </a>
         ]. A systematic review and meta-analysis of randomized controlled studies that compared azithromycin with
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         found no difference in the outcome of treatment with either drug regimen [
         <a href="#rid29">
          29
         </a>
         ]. Studies of treatment for otitis media are highly dependent upon (1) the methods used to make the clinical diagnosis, (2) the methods used to establish the bacteriologic diagnosis, and (3) the methods used to define cure, and response to a placebo has been documented in careful prospective studies. As the proportion of cases of otitis due to pneumococci declines and the proportion due to
         <em>
          Haemophilus
         </em>
         increases, one might expect better outcomes with macrolide therapy, but empiric treatment with a macrolide for otitis media is
         <strong>
          not
         </strong>
         recommended, although it could be considered in patients who cannot take beta-lactam antibiotics.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Sinusitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some studies,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (500 mg daily for 3 to 5 days) or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         (500 mg twice daily for 10 to 14 days) effectively treated patients with acute bacterial sinusitis [
         <a href="#rid30">
          30,31
         </a>
         ]. A study from Croatia where, at the time, 25 percent of pneumococci were
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         resistant [
         <a href="#rid32">
          32
         </a>
         ] showed a 95 percent cure rate by azithromycin [
         <a href="#rid33">
          33
         </a>
         ]. These results might support the notion of a discrepancy between in vitro and in vivo resistance to this class of drugs, but a limitation of such studies is that most cases of sinusitis eventually resolve spontaneously, many cases of sinusitis are of viral etiology, and the outcome of any study is determined by the severity of disease in the patients who are included. Macrolides are
         <strong>
          not
         </strong>
         recommended for empiric therapy of bacterial sinusitis. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">
          "Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of the literature on macrolide resistance in pneumonia deals with groups of patients who are lumped together under the diagnosis of "community-acquired pneumonia" (CAP). CAP is a heterogenous syndrome that can be caused by a variety of pathogens in addition to pneumococcus and, for a substantial proportion of cases, the causative pathogen is not known. Treatment regimens frequently include a macrolide plus a second antibiotic. When the use of macrolide monotherapy has been reported, the absence of an identified etiologic agent renders it impossible to interpret the results [
         <a href="#rid28">
          28
         </a>
         ]. In evaluating reports of responses to therapy, it is essential to note the years during which patients were studied and the prevailing rate and level of resistance at those times, which is clearly a "moving target" in recent years. Thus, determining the relationship among drug levels, inhibitory concentrations, and clinical outcomes is very difficult.
        </p>
        <p>
         While the Infectious Diseases Society of America and American Thoracic Society guidelines for the treatment of CAP conditionally recommend either
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         for CAP treatment in selected otherwise healthy outpatients in areas where &lt;25 percent of pneumococcal isolates are macrolide resistant (ie, MIC ≥16 mcg/mL), such areas are uncommon, and clinicians typically do not know local resistance rates. Therefore, we do not routinely recommend empiric macrolide monotherapy.
         <em>
          S. pneumoniae
         </em>
         is the most potentially dangerous pathogen and the clinician should not miss this pathogen when selecting an empiric regimen. (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting", section on 'Empiric antibiotic treatment'
         </a>
         .)
        </p>
        <p>
         Macrolide monotherapy is not recommended for the treatment of hospitalized patients with CAP, but macrolides and azalides are commonly used in the United States as part of a combination regimen. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          LINCOSAMIDES
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         is the only lincosamide in current use.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Mechanisms of action and resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although structurally different from the macrolides,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         acts at the same site in the ribosome, and its activity is blocked if the site is methylated; thus, pneumococci that have the
         <em>
          ermB
         </em>
         mutation are also resistant to clindamycin. However, this drug is not excluded from bacterial cells by the efflux pump, and
         <em>
          mefA
         </em>
         does not convey resistance.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Prevalence of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 5 to 10 percent of pneumococci in the United States are resistant to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         with regional variation, as noted above [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Treatment and response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon relatively limited clinical data,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         provides effective therapy for pneumococcal pneumonia due to susceptible isolates [
         <a href="#rid35">
          35
         </a>
         ], but it is not recommended for pneumonia of uncertain etiology because of the lack of efficacy against other common pathogens such as
         <em>
          H. influenzae
         </em>
         ,
         <em>
          M. catarrhalis
         </em>
         ,
         <em>
          Legionella
         </em>
         spp, and
         <em>
          M. pneumoniae
         </em>
         .
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rising rates of macrolide resistance
         </strong>
         – The macrolides were important agents for treating otitis media, sinusitis, and outpatients with community-acquired pneumonia (CAP) in the past, in large measure because of their excellent activity against pneumococci. However, increases in the proportion of pneumococci that are resistant to macrolides have reduced the utility of macrolides for these conditions. (See
         <a class="local">
          'Macrolides and azalides'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy of
         </strong>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         – Clindamycin is effective against pneumococci that have
         <em>
          mefA
         </em>
         resistance but not against those that have
         <em>
          ermB
         </em>
         ; the lack of activity against other respiratory pathogens (eg,
         <em>
          Haemophilus influenzae
         </em>
         ) limits the utility of this drug in otitis media, acute bacterial sinusitis, or CAP unless pneumococci are known to be responsible. (See
         <a class="local">
          'Lincosamides'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Visalli MA, Jacobs MR, Appelbaum PC. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagn Microbiol Infect Dis 1997; 28:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry V, Thorburn CE, Knott SJ, Woodnutt G. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42:3193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013; 75:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim L, McGee L, Tomczyk S, Beall B. Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective. Clin Microbiol Rev 2016; 29:525.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. 2019. Active Bacterial Core Surveillance Report, Emerging
Infections Program Network, Streptococcus pneumoniae, 2019. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf (Accessed on February 04, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munson E, Lavey SC, Lasure MR, Fox BC. Changes in Streptococcus pneumoniae Susceptibility in Wisconsin: Implications for Clinical Treatment Decisions for Respiratory Infections. Clin Med Res 2022; 20:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohanty S, Johnson KD, Yu KC, et al. A Multicenter Evaluation of Trends in Antimicrobial Resistance Among Streptococcus pneumoniae Isolates From Adults in the United States. Open Forum Infect Dis 2022; 9:ofac420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48:e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simões AS, Pereira L, Nunes S, et al. Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing Pneumococci in the PCV7 era in Portugal. J Clin Microbiol 2011; 49:2810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45:3334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2:S81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hotomi M, Billal DS, Shimada J, et al. Increase of macrolide-resistant Streptococcus pneumoniae-expressing mefE or ermB gene in the nasopharynx among children with otitis media. Laryngoscope 2005; 115:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mykhalko YO, Duhovych TV, Kish PP. Susceptibility of streptococcus pneumoniae to fluoroquinolones and macrolides in upper respiratory tract infections. Wiad Lek 2017; 70:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keenan JD, Klugman KP, McGee L, et al. Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments. J Infect Dis 2015; 211:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keenan JD, Bailey RL, West SK, et al. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med 2018; 378:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doan T, Arzika AM, Hinterwirth A, et al. Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger. N Engl J Med 2019; 380:2271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J 2000; 19:S57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kogan R, Martínez MA, Rubilar L, et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr Pulmonol 2003; 35:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawit G, Mequanent S, Makonnen E. Efficacy and safety of azithromycin and amoxicillin/clavulanate for otitis media in children: a systematic review and meta-analysis of randomized controlled trials. Ann Clin Microbiol Antimicrob 2021; 20:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayle R, Lingaas E, Høivik HO, Odegård T. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1996; 15:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray JJ, Solomon E, McCluskey D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin Ther 2000; 22:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tambic Andrasevic A, Tambic T, Kalenic S, et al. Surveillance for antimicrobial resistance in Croatia. Emerg Infect Dis 2002; 8:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klapan I, Culig J, Oresković K, et al. Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999; 20:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherubin CE, Magazine D, Hargrove C, et al. A comparative study of the treatment of presumed pneumococcal pneumonia: parenteral penicillin and clindamycin with continuation on oral therapy. Curr Ther Res Clin Exp 1975; 17:88.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7033 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9294703" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9835514" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988052" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524961" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15752529" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11083646" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856810" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Emergence of macrolide resistance during treatment of pneumococcal pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23009730" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27076637" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27076637" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36581396" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Changes in Streptococcus pneumoniae Susceptibility in Wisconsin: Implications for Clinical Treatment Decisions for Respiratory Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36168549" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A Multicenter Evaluation of Trends in Antimicrobial Resistance Among Streptococcus pneumoniae Isolates From Adults in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19115971" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19751588" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Increase in pneumococcus macrolide resistance, United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21632898" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing Pneumococci in the PCV7 era in Portugal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709305" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11320449" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155207" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15689758" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Increase of macrolide-resistant Streptococcus pneumoniae-expressing mefE or ermB gene in the nasopharynx among children with otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28511165" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Susceptibility of streptococcus pneumoniae to fluoroquinolones and macrolides in upper respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15825031" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Predicting antimicrobial resistance in invasive pneumococcal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25293366" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29694816" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31167060" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10693993" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10602721" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10821473" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12526069" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33894769" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy and safety of azithromycin and amoxicillin/clavulanate for otitis media in children: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8997555" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11192134" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11749742" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Surveillance for antimicrobial resistance in Croatia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950107" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983908" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/806433" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A comparative study of the treatment of presumed pneumococcal pneumonia: parenteral penicillin and clindamycin with continuation on oral therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
